Recruiting

Observational Study

Sponsor:

Jennifer Whitwell

Code:

NCT07000851

Conditions

Cortico Basal Degeneration

Corticobasal Syndrome

Corticobasal Syndrome(CBS)

Corticobasal Degeneration

Corticobasal Degeneration (CBD)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

C-11 ER176 Radiotracer

C-11 PiB

AV1451 Tau

Study Details

Brief summary:

The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.

Conditions

Cortico Basal Degeneration

Corticobasal Syndrome

Corticobasal Syndrome(CBS)

Corticobasal Degeneration

Corticobasal Degeneration (CBD)

Study ID

NCT07000851

Start date

Jun 25, 2025

Status verified date

Jul, 2026

Completion date

Mar 30, 2031

Anticipated

Primary completion date

Mar 30, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age 18 years or older
  • Meet possible or probable CBS criteria

Exclusion Criteria:

  • Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)
  • Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome
  • Subjects will be excluded if they have a mutation in the progranulin gene
  • Subjects will excluded if they have received anti-Aβ therapy
  • Women who are pregnant will be excluded
  • Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)
  • Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning

Study Design

Enrollment

80 participants

Anticipated

Interventions and Outcome Measures

Arms

Corticobasal Syndrome

patients diagnosed with cbs

Healthy Control

Healthy Control Volunteer

Interventions

C-11 ER176 Radiotracer

PET scan looking for inflammation

C-11 PiB

PET scan looking for amyloid protein

AV1451 Tau

Pet scan looking for Tau protein

Primary outcome measure

  • The investigators will use C-11 ER176 PET imaging to evaluate neuroinflammation and white matter integrity in CBS [ Time Frame: approximately 4-5 years into study visits ]

Central Contacts and Locations

Central contacts

Megan J Meyer, M.B.A.

507-293-1164meyer.megan6@mayo.edu

Sarah M Boland, CCRP

507284-3863boland.sarah@mayo.edu

Locations

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

More Information

Sponsor

Jennifer Whitwell

Last update posted

Jul 14, 2026

Last verified

Jul, 2026

Keywords

  • neurodegeneration
  • neurodegenerative disease
  • cbs
  • cbd
  • corticobasal syndrome
  • corticobasal degeneration

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Jennifer Whitwell on 2026-07-14.